|1.||Han, Rong: 3 articles (08/2007 - 03/2005)|
|2.||Qin, Zheng-Hong: 2 articles (08/2006 - 03/2005)|
|3.||Milackova, Ivana: 1 article (01/2016)|
|4.||Sánchez-Murcia, Pedro A: 1 article (01/2016)|
|5.||García-Martín, Elena: 1 article (01/2016)|
|6.||Díez-Dacal, Beatriz: 1 article (01/2016)|
|7.||Agúndez, José A G: 1 article (01/2016)|
|8.||Gago, Federico: 1 article (01/2016)|
|9.||Gharbi, Severine: 1 article (01/2016)|
|10.||Sánchez-Gómez, Francisco J: 1 article (01/2016)|
09/01/1998 - "We also show that, as reported in studies of different virus/host cell models, PGA1 inhibits HIV-1 replication by acting at multiple levels during HIV-1 infection. "
06/01/1995 - "Induction of hsp70 has been associated with a cytoprotective effect of PGA1 after virus infection or thermal injury. "
05/01/1995 - "Interestingly, HSP70 transcript and protein persisted at remarkably high levels in Molt-4 cells exposed to HTLV-I in the absence of PGA1, showing that HSP70 expression can be directly activated during primary infection with this human retrovirus. "
05/01/1995 - "PGA1, a powerful inhibitor of tumour cell proliferation, can prevent the clonal expansion of HTLV-I-infected cells following acute infection of cord blood-derived mononuclear cells. "
11/01/1991 - "Virus adsorption and penetration do not appear to be targets of antiviral action because PGA1 substantially reduced virus replication, even when added 5 h post-infection. "
04/01/1980 - "In addition to its effect on tumor size, PGA1 was also effective in stimulating both the humoral and cellular components of the immune response. "
04/01/1980 - "Although, PGA1 had relatively little effect on normal mice, this prostaglandin substantially improved all these immunologic parameters in tumor-bearing animals."
07/01/2000 - "PGA1 was also found to induce the loss of the tumor suppressor p53 protein, in the "proliferative" conformation, in a time correlation with the induction of the HSP70 As the "proliferative" p53 has been involved in the positive trans-activation of the HIV-1 LTR its depletion could contribute to the inhibitory mechanisms of PGA1 on virus transcription."
04/01/1988 - "Structural identification of prostaglandin A1 biotransformation products from tumor cells."
12/30/1986 - "Tumor cell biotransformation products of prostaglandin A1 with growth inhibitory activity."
01/01/1992 - "Such promising data add another important perspective to prostaglandin A1 in severe pre-eclampsia and may open up new avenues for its use in other situations with compromised placental flow."
01/01/1992 - "Improving placental blood flow in pre-eclampsia with prostaglandin A1."
07/01/1988 - "Treatment of preeclampsia with prostaglandin A1."
01/01/1983 - "Twenty one cases of severe pre-eclampsia (in 3 equal groups) received i.v. infusions of PGA1 in a dose range of 0.1-0.5 microgram/kgm/min for 12 - 24 hours and the B.P., uterine activity and FHR were continuously monitored during and for 12 hours following the infusion period. "
01/01/1983 - "Therapeutic use of PGA1 infusions in severe pre-eclampsia - a major clinical potential."
|4.||Neurodegenerative Diseases (Neurodegenerative Disease)
04/01/2001 - "In view of its potent neuroprotective activity, PGA1 could prove useful in the treatment of certain neurodegenerative disorders related to excitotoxicity."
04/01/2001 - "Since both these effects could be neuroprotective, the therapeutic potential of PGA1 in neurodegenerative disorders, where excitotoxicity may contribute to pathogenesis, was evaluated in rat striatal neurons exposed to the N-methyl-D-aspartate (NMDA) receptor agonist quinolinic acid (QA). "
|5.||Critical Illness (Critically Ill)
|1.||prostaglandin A1 (PGA1)
|2.||RNA (Ribonucleic Acid)
|3.||Chloramphenicol O-Acetyltransferase (Chloramphenicol Acetyltransferase)
|6.||Heat-Shock Proteins (Heat-Shock Protein)
|7.||Messenger RNA (mRNA)
|3.||Drug Therapy (Chemotherapy)